10x Genomics (TXG) Asset Writedowns and Impairment (2023 - 2025)

10x Genomics has disclosed Asset Writedowns and Impairment across 3 years of filings, most recently posting $114000.0 for Q1 2025.

• Asset Writedowns and Impairment for Q1 2025 came in at $114000.0, down 95.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $114000.0 (down 84.03% YoY), and the FY2025 annual result was $814000.0, down 73.35% from the prior year.
• Asset Writedowns and Impairment came in at $114000.0 for Q1 2025 at 10x Genomics, down from $600000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $7.1 million in Q4 2023 to a low of $114000.0 in Q1 2025.
• The 3-year median for Asset Writedowns and Impairment is $2.5 million (2024), against an average of $2.6 million.
• Across the five-year window, Asset Writedowns and Impairment sank 91.5% in 2024 and slumped 95.35% in 2025, its largest moves.
• 10x Genomics' Asset Writedowns and Impairment stood at $7.1 million in 2023, then tumbled by 91.5% to $600000.0 in 2024, then slumped by 81.0% to $114000.0 in 2025.
• The last three Asset Writedowns and Impairment figures came in at $114000.0 (Q1 2025), $600000.0 (Q4 2024), and $2.5 million (Q1 2024), per Business Quant data.